foxo4-dri vs gdf-11

foxo4-dri vs gdf-11 Structural basis for potency differences between GDF8 and GDF11 | BMC Biology The disordered p53 transactivation domain

Name: foxo4-dri vs gdf-11 Structural basis for potency differences between GDF8 and GDF11 | BMC Biology The disordered p53 transactivation domain
Brand: www.coppermineslodge.com
SKU: 78791854346
Price: 23.93 USD
Availability: InStock
Rating: 4.3582 (14 reviews)

The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice PMC Deficiency of GDF 11 Accelerates TAC Induced Heart Failure by Impairing Cardiac Angiogenesis JACC: Basic to Translational Science Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine FOXO4 DRI: The Senolytic Peptide That Targets Zombie Cells and Aging Revolution Health & Wellness Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry

SKU: 78791854346 · From www.coppermineslodge.com

4.4

USD23.93 USD71.93

Pay in 4 interest-free payments of $5.98 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Jul 30 - Aug 4

Description

References and Storage Sources Peptide stability guidance is consistent on the main principle: dry peptide powder is more stable than peptide solution, and reconstituted peptides require shorter, colder, cleaner handling